Masimo (MASI) Gets FDA Nod For RRp Monitoring Technology

Masimo Corporation (NASDAQ:MASI) recently obtained FDA clearance for the continuous RRp (respiration rate from the photoplethysmograph) monitoring of adult and pediatric patients with Rad-97, Radical-7 and Radius-7 Pulse CO-Oximeters.

With this go-ahead, both continuous and spot-check RRp are now commercially available in the United States. It is supported by a wide range of pulse oximetry sensors and configurations, including the new non-cabled, tetherless, wearable Radius PPG.

The FDA clearance of this monitoring system is expected to strengthen the company’s portfolio of pulse oximetry technologies.

More About the RRp Monitoring

The availability of continuous RRp perfectly complements Masimo’s diverse portfolio of respiration rate monitoring modalities that consists of acoustic respiration rate (RRa), NomoLinecapnography (RRc) and now, photoplethysmographic respiration rate (RRp).

Acoustic respiration rate, RRa, has been proved to be a precise, reliable and convenient method of monitoring respiration rate on a continuous basis. However, in situations where RRa or RRc is not available, RRp offers a convenient way to precisely obtain RR for patients whose arterial oxygen saturation (SpO₂) is already being monitored using Masimo SET. RRp is particularly designed to adapt to lower acuity settings like the general ward, where there is a scarcity of respiration rate monitoring technologies for patients.

The availability of RRp should be instrumental in aiding physicians and public health officials to combat respiratory-related illnesses, including the COVID-19, especially when using an additional sensor is not an option.

Alongside RRp, Masimo SET sensors offer Measure-through Motion and Low Perfusion SET pulse oximetry, which has been clinically proven to be superior to other pulse oximetry technologies in more than 100 independent and objective studies.

Market Prospects

Per Grand View Research, the global pulse oximeters market reached a worth of $1.8 billion in 2018 and is anticipated to see a CAGR of 6.3% over the forecast period of 2019-2025. Hence this FDA clearance comes at an ideal time.

Recent Developments

Last year, Masimo received another regulatory go-ahead, which boosted its portfolio of pulse oximetry technologies.

In December 2019, Masimo attained FDA clearance for the RD SET sensors with Masimo Measure-through Motion and Low Perfusion SET pulse oximetry. This technology is developed to improve SpO₂ accuracy specifications for neonatal patients.

Price Performance

In the past year, the company’s shares have outperformed the industry. The stock has rallied 33.2% against the industry’s 3.4% decline.

Zacks Rank and Other Key Picks

Masimo currently carries a Zacks Rank #2 (Buy).

A few other top-ranked stocks from the broader medical space are ResMed (NYSE:RMD) , Medtronic (NYSE:MDT) and Hill-Rom Holdings (NYSE:HRC) .

ResMed has an estimated long-term earnings growth rate of 12%. It currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Medtronic’s long-term earnings growth rate is projected at 7.4%. The company presently carries a Zacks Rank #2.

Hill-Rom’s long-term earnings growth rate is estimated at 11.1%. It currently carries a Zacks Rank #2.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>